Virogenomics BioDevelopment, Inc. (VBD) was spun out of Oregon Health Science University (OHSU) and Virogenomics, Inc. (VG) in 2015. VBD’s executives continue the mission they led at VG, which was to identify, obtain, and then develop rights to early-stage technologies for drug discovery and development. While at VG, Jeff and Renee entered into several technology transfer agreements with several universities, including OHSU, in three areas: autoimmune diseases, stroke, and infectious diseases. Four companies were spun out of VG including Artielle ImmunoTherapeutics, a privately-held clinical-stage pharmaceutical development company. Under VG management, Artielle raised $19M in venture financing to complete a Phase 1 clinical trial to treat multiple sclerosis.